UBS Group
DMIIU

UBS Group’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

UBS Group’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
1,765
+2
+0.1% +$20 ﹤0.01% 8224
2026
Q1 		$17.7K Sell
1,763
-91,707
-98% -$922K ﹤0.01% 8019
2025
Q4 		$936K Buy
+93,470
New +$936K ﹤0.01% 5633

Other funds holding DMIIU

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group's DMIIU Position: Q2 2026 in Review

UBS Group increased its Drugs Made In America Acquisition II Corp Unit (DMIIU) stake by 0.11% in Q2 2026, buying an estimated $20 and bringing the position to 1,765 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8224.

UBS Group first reported a position in DMIIU in Q4 2025 and has held it in 3 quarters since. The position peaked at $936K in Q4 2025. 11 funds tracked by Wall St. Rank hold DMIIU as of Q2 2026.

  • UBS Group held 1,765 shares of Drugs Made In America Acquisition II Corp Unit worth $17.9K as of Q2 2026.
  • UBS Group bought 2 Drugs Made In America Acquisition II Corp Unit shares in Q2 2026, an estimated $20.
  • Drugs Made In America Acquisition II Corp Unit made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8224 holding.
  • UBS Group first reported a position in Drugs Made In America Acquisition II Corp Unit in Q4 2025 and has held it in 3 quarters since.
  • UBS Group's Drugs Made In America Acquisition II Corp Unit position peaked at $936K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.